Norovirus infects 700 million individuals each year, causing more than 200,000 deaths and there is no current preventive nor antiviral therapies against this disease. Hence, this project aims to develop NoV-VLPs and NoV-specific nanobodies as preventative and therapeutic applications. The adenovirus expression system was utilized to produce NoV-VLPs for HuNoV GII.4 and MNV CW3 (murine). The sequences were cloned into the pAdTrack-CMV vector, and the constructed DNA was subjected to electroporation into recombinant bacteria containing the adenovirus backbone, resulting in the pAdEasy vector. This recombinant DNA was then transfected into HEK-293A cells to create the adenovirus stock. The adenovirus stock was used to infect Vero cells, leading to the production of Norovirus VLPs. After infecting Vero cells with the adenovirus, the successful infection was confirmed by verifying the fluorescence of the cells. The vector also carried the GFP gene, so the green, fluorescent cells indicated infection by the recombinant adenovirus. Following verification, we harvested the cells and performed Western blot analysis, which demonstrated the presence of VP1 (NoV capsid protein) inside the cells. Once VP1 presence was confirmed, the infection was scaled up and all the cells were harvested, lysed, concentrated, and purified. The purified VLP samples were then examined by electron microscopy, verifying that the particles were of the correct size and shape. The purified samples were also submitted to western blot and the presence of the VP1 was confirmed. As a future perspective, the purified VLPs will also be produced using the baculovirus expression system (BEVS) and they will be used as antigen to immunize mice and assess their ability to generate antibodies, and to immunize alpacas and generate NoV-specific nanobodies.